Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Cholangiocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00350753
What this trial is testing

Avastin and Tarceva for Upper Gastrointestinal Cancers

Who this might be right for
CholangiocarcinomaGallbladder Cancer
Rigshospitalet, Denmark 126
Testing effectiveness (Phase 2)Study completedNCT04072445
What this trial is testing

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Who this might be right for
Advanced Bile Duct CarcinomaAdvanced Gallbladder CarcinomaRefractory Bile Duct Carcinoma+15 more
Mayo Clinic 28
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03058289
What this trial is testing

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Who this might be right for
Breast CancerHead and Neck CancerSquamous Cell Carcinoma+8 more
Intensity Therapeutics, Inc. 111
Early research (Phase 1)Study completedNCT04676633
What this trial is testing

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Who this might be right for
Hepatocellular CarcinomaLiver MetastasesCholangiocarcinoma
Sirnaomics 5
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Looking for participantsNCT06302621
What this trial is testing

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital 70
Testing effectiveness (Phase 2)Study completedNCT01290536
What this trial is testing

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Who this might be right for
Colorectal NeoplasmsNeuroendocrine TumorsCholangiocarcinoma+2 more
Nicholas Fidelman, MD 42
Testing effectiveness (Phase 2)Study completedNCT02042443
What this trial is testing

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Who this might be right for
Adult CholangiocarcinomaAdvanced Adult Hepatocellular CarcinomaBCLC Stage C Adult Hepatocellular Carcinoma+16 more
National Cancer Institute (NCI) 53
Early research (Phase 1)Ended earlyNCT06420349
What this trial is testing

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Who this might be right for
Advanced CholangiocarcinomaMetastatic CholangiocarcinomaRefractory Cholangiocarcinoma+4 more
Mayo Clinic 7
Testing effectiveness (Phase 2)UnknownNCT04298008
What this trial is testing

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Who this might be right for
Bile Duct CancerChemotherapy Effect
Seoul National University Hospital 26
Testing effectiveness (Phase 2)Ended earlyNCT04566133
What this trial is testing

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Who this might be right for
Bile Duct CancerBiliary CancerBiliary Tract Neoplasms+1 more
National Cancer Institute (NCI) 2